Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Rhea-AI Summary

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced receipt of a transparency notification as of December 10, 2021, indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has crossed the 25% ownership threshold. This entity now holds 6,500,000 shares, representing 28.77% of Celyad's shares and 26.04% of voting rights as of December 8, 2021. The notification is a legal requirement following the acquisition of voting securities, affirming Fortress's significant stake in the company.

Positive

• Fortress Investment Group has increased its stake to 28.77%, indicating strong confidence in Celyad's prospects.
• Acquisition of 6,500,000 shares may lead to enhanced governance and strategic direction.

Negative

• None.

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 10, 2021 indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 25%, holding 6,500,000 shares i.e. 28.77% of Celyad Oncology’s shares and 26.04% voting rights as of 8 December 2021.

Content of the Notification:

• Reason of the Notification:
  Upward crossing of the 25% threshold
  Acquisition of voting securities or voting rights
• Notification by:
  A parent undertaking or a controlling person
• Persons subject to the notification requirement:
  Fortress Investment Group LLC. – 1345 Avenue of the Americas, 46^th Floor, New York, NY 10105 USA
  CFIP CLYD LLC – 1345 Avenue of the Americas, 46^th Floor, New York, NY 10105 USA
• Transaction date
  December 8, 2021
• Threshold that is crossed (in %)
  25
• Denominator
  22,593,956
• Notified details:

A) Voting Rights	Previous notification	After the Transaction
	#of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to the securities	Not linked to the securities	Linked to the securities	Not linked to the securities
Fortress Investment Group LLC		0		0.00%
CFIP CLYD LLC		6,500,000		26.04%
Subtotal		6,500,000		26.04%
	TOTAL	6,500,000		26.04%

• Chain of controlled undertakings through which the holdings is effectively held
  Fortress Investment Group LLC indirectly controls 100% of the members of CFIP CLYD LLC, which are various Fortress Funds. Fortress Investment Group LLC has no controlling shareholder.

Miscellaneous

• The Press Release may be consulted on the website of Celyad Oncology via this link.
  The notification can be consulted on the website if Celyad Oncology via this link.
• Contact person(s):
  By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the clinical activity and safety and tolerability of CYAD-211 and expectations regarding enrollment and the announcement of additional clinical data, and the clinical activity and safety and tolerability of the CYAD-02 and CYAD-101 programs. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005902/en/

Investor and Media Contacts:



Sara Zelkovic

Communications & Investor Relations Director

Celyad Oncology

investors@celyad.com



Daniel Ferry

Managing Director

LifeSci Advisors, LLC

daniel@lifesciadvisors.com

Source: Celyad Oncology SA

FAQ

What is the significance of Fortress Investment Group's stake in Celyad Oncology (CYAD)?

Fortress Investment Group now holds 28.77% of Celyad Oncology's shares, which can influence company decisions and indicates investor confidence.

When did Fortress Investment Group cross the 25% ownership threshold in Celyad (CYAD)?

Fortress crossed the 25% ownership threshold on December 8, 2021.

How many shares does CFIP CLYD LLC own in Celyad Oncology (CYAD)?

CFIP CLYD LLC holds 6,500,000 shares of Celyad Oncology.

What is the percentage of voting rights held by Fortress Investment Group in Celyad (CYAD)?

Fortress Investment Group holds 26.04% of the voting rights in Celyad Oncology.